Clinical Proteomic Tumor Analysis Consortium (CPTAC)

Pathology and Biorepository Core

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a National Institutes of Health-led, multi-institutional effort to improve the understanding of cancer biology through genomic and proteomic analysis. CPTAC is supported by NIH’s National Cancer Institute (NCI), and is comprised of more than 30 organizations across the U.S. and abroad.

CPTAC plans to collect 200 samples each from 10 tumor types, including lung, pancreas, brain, kidney, uterine, bone, skin, head and neck, and blood cancers. As the Biospecimen Core Resource for the project, VARI’s Biorepository compiles the kits for sample procurement and, upon receipt of the samples, processes the them into analytes and sends them downstream for genomic and proteomic analysis, including copy number variation; single-nucleotide polymorphisms; DNA, RNA and protein expression; and mutation analyses. Each case is qualified through pathologic and molecular verification at VARI’s Biorepository prior to downstream analysis. De‐identified data is available through the CPTAC Data Coordinating Center and other NIH data resources.

Samples collected:

  • Lung adenocarcinoma (LUAD)
  • Pancreatic ductal adenocarcinoma (PDA)
  • Glioblastoma multiforme (GBM)
  • Acute myeloid leukemia (AML)
  • Clear cell renal cell carcinoma (CCRCC)
  • Head and neck squamous cell carcinoma (HNSCC)
  • Cutaneous melanoma (CM)
  • Sarcomas (SAR)
  • Lung squamous cell carcinoma (LSCC)
  • Uterine corpus endometrial carcinoma (UCEC)